AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 474 participants.

Also called NCT07030595

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 474 participants (enrolled count) (from the registry)
Sponsor
Alebund Pharmaceuticals (from the registry)
Registry
  • NCT NCT07030595
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07030595. Randomized; no masking; primary purpose treatment. Start 2023-06-12 (actual); primary completion 2024-10-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
Acronym
RESPOND-1
Condition
ESRD (End Stage Renal Disease)
Condition
Hyperphosphatemia
Condition
Hyperphosphatemia in Chronic Kidney Disease
Condition
Dialysis
Condition
Chronic Kidney Disease, Receiving Dialysis
Intervention (Drug)
AP301
Intervention (Drug)
Sevelamer carbonate (Renvela®)
Intervention (Drug)
AP301 Low Dose
Lead sponsor
Alebund Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07030595
Content hash
275d49ea3c969f1f6026e3bcc6d17c5d8e285bb4755a1e80b751f0ef57459366